Domestic pharmaceutical firms mull product restructuring

Published: 2004-05-07 07:00:00

Updated: 2004-05-07 07:00:00

A number of domestic pharmaceutical firms are gearing up to concentrate their efforts on profit-making items via intensive product restructuring program designed to eliminate some items with little marketability, lower insurance price, less frequency of prescription and no production record.

A...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK